Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05387707 · ClinicalTrials.gov registry record · Phase 3
Study to Evaluate the Efficacy and Safety of Oral Difelikefalin as Adjunct Therapy to a Topical Corticosteroid for Moderate to Severe Pruritus in Subjects With Atopic Dermatitis
A Phase 3 study, sponsored by Cara Therapeutics.
- Terminated
- Registry status
- Phase 3
- Development phase
- 287
- Enrollment target
NCT05387707 is a Phase 3 study that was terminated before completion, run by Cara Therapeutics. The registered enrollment target is 287 participants.
The verdict
NCT05387707, a Phase 3 study, was terminated before completion, sponsored by Cara Therapeutics.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 287 participants
- Enrollment target
Study Summary
This is a two-part, multicenter, randomized, double-blind study to evaluate the efficacy and safety of oral difelikefalin as adjunct therapy to a topical corticosteroid (TCS) for moderate-to-severe pruritus in adult subjects with atopic dermatitis (AD).
Interventions
- DRUG Placebo
- DRUG Vehicle Cream
- DRUG TCS Cream
- DRUG difelikefalin 0.25 mg
- DRUG difelikefalin 0.5 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 287 participants |
| Start Date | 2022-08-16 |
| Est. Completion | 2024-02-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05387707
The ClinicalTrials.gov registry entry for NCT05387707 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 287 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cara Therapeutics, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT05387707 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05387707 about?
NCT05387707 is a clinical study titled "Study to Evaluate the Efficacy and Safety of Oral Difelikefalin as Adjunct Therapy to a Topical Corticosteroid for Moderate to Severe Pruritus in Subjects With Atopic Dermatitis". This is a two-part, multicenter, randomized, double-blind study to evaluate the efficacy and safety of oral difelikefalin as adjunct therapy to a topical corticosteroid (TCS) for moderate-to-severe pruritus in adult subjects with atopic dermatitis (AD).
What is the current status of trial NCT05387707?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 287 participants. The study started on 2022-08-16. Estimated completion is 2024-02-02.
What interventions are being tested in trial NCT05387707?
The interventions under investigation include: Placebo (DRUG), Vehicle Cream (DRUG), TCS Cream (DRUG), difelikefalin 0.25 mg (DRUG), difelikefalin 0.5 mg (DRUG).
Who is sponsoring clinical trial NCT05387707?
This trial is sponsored by Cara Therapeutics, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.